As part of our ongoing commitment to deliver innovation in the areas of highest unmet need, we have created a £10 million seed fund. The fund specifically supports partnerships with organisations that focus on the evidence base for paediatric care and treatment, the research and development of paediatric fixed-dose combination (FDC) products, and formulations for the treatment of infants and children living with HIV. Joint efforts to improve access to therapy and care include:

• A non-monetary Memorandum of Understanding with the Clinton Health Access Initiative (CHAI) aimed at developing an affordable new FDC for paediatric use.
• The ViiV Healthcare-Elizabeth Glaser Pediatric AIDS Foundation Partnership to increase early detection of HIV and improve access to antiretroviral therapy for HIV-positive infants and young children; strengthen government leadership and policies around paediatric HIV/AIDS; and improve the quality and use of paediatric care to advance the effectiveness of its services.
• The ViiV Healthcare-amfAR TREAT Asia programme to optimise the quality of healthcare for infants and children living with HIV across Asia through the development of clinical data to support optimal paediatric treatment guidelines.